The tech scene is currently booming in New Zealand, with more and more innovative companies coming up every week.

As we enter a new year, many tech companies are ready to make 2023 their year.

From financial ventures to breakthroughs in the health industry, we have combined a list of some of the tech companies that we should keep an eye on in this new year.

Dolla

Coming off the back of Covid-19, where many have ditched the physical wallet and are now using the likes of Apple and Samsung pay, Dolla is a platform that truly sees the end of the wallet.

Dolla is a payment platform that makes transferring funds between any New Zealand bank account simple through QR codes.

Whether it be requesting, sending payments, splitting or paying bills, Dolla is pioneering the finance infrastructures of New Zealand with its innovation.

“Our mission is to create an intelligent, low cost, domestic payments platform that sits on top of our existing inter-bank settlement network,” says Ben Lynch, CEO at Dolla.

“We believe this is a critical component of our National Digital Infrastructure (NDI) and we’re super passionate about ensuring Aotearoa has its own domestic payments platform to rival the current overseas based card scheme networks.”

Already seeing success in its first 12 months as its sees traction within its merchant offerings, 2023 is expected to be another big year.

“We’ve got a huge next 12 months in front of us as we complete our funding round which will enable us to significantly scale up our team and build out our product offering in order to deliver on our ambitious plans to provide all Kiwis with an intelligent, low cost, domestic payments platform to be proud of.”

Zeronet

Recently launched in December, Zeronet is the country’s very first sustainable internet provider.

Karrim Hussona, Co-founder and CEO of Zeronet says the company will be offsetting all its carbon emissions through planting trees to create “a better world”.

“It means that the customers themselves can be contributing. They can be not only browsing in a carbon neutral way, but they contributed towards something that is trying to fix the problem,” he says.

Alongside purchasing carbon credits and being run solely on solar power, Hussona says they are taking it one step further and investing on projects and schemes that will recover carbon in the atmosphere and generate renewable energy.

“We’d like to get to the point where we are, through the efforts of our customers, removing at least 5,000 tonnes of carbon a year,” adds Hussona.

Read more: Partly becomes New Zealand’s fastest growing start-up company

Partly

Now named New Zealand’s fastest growing start-up company, the parts technology company is a platform that connects automotive buyers and sellers together in a more efficient and precise way.

Partly is aiming to address the industry that has a value of $1.9 trillion through an algorithm platform based on compatibility, data and infrastructure.

Something no one has ever done before.

“This is an incredibly difficult technical problem that nobody has cracked,” says CEO and ex-Rocket Lab engineer, Levi Fawcett.

In a recent round of funding led by Europe’s leading venture capitalist firm, Octopus Ventures, Partly was able to raise $37 million, the largest amount in start-up history.

Now valued near $180 million, Partly is hoping to expand to better fit the global environment.

“We’re looking for the most outstanding software engineers globally who are excited about solving hard problems.”

Exsurgo

Heading into 2023, Exsurgo is continuing to pioneer the neuro technology space as the new year marks as a “significant” step toward “large-scale commercialisation” of its product, Axon.

Working towards alleviating chronic pain, Axon is a headset given to patients to decrease pain, improve mental health and quality of life.

The product is introduced to deal with the challenging costs the country is seeing which is costing over $13 billion a year.

2022 was the year for Exsurgo to undergo the largest clinical trial for the product, with the results set to hit the beginning of 2023.

Results to prove Axon’s efficacy, which has already been seen in countries such as the US and the UK, will further Exsurgo’s international investor interest to support mass production.

“2023 will be a pivotal year for Exsurgo as we edge closer to making Axon accessible to millions of chronic pain sufferers around the world, via clinician prescriptions,” says CEO Richard Little.

“Our team of entrepreneurs, scientists and engineers has worked tirelessly over the past few years to design and engineer clinically validated medical products that ease suffering and enhance human potential.”